Healthcare & Life Sciences
XWPharma
China
aliveseries-c-plus
series-c-plus
Stage
1
Investors
About
XWPharma is a Wuhan-based biopharmaceutical company focused on discovering and developing therapeutics for neurological and psychiatric disorders, with its lead program being a Phase 2 oral NMDA antagonist for treatment-resistant depression.
Explore XWPharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.